KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Gross Margin: 2011-2023

Historic Gross Margin for TherapeuticsMD (TXMD) over the last 12 years, with Dec 2023 value amounting to 100.00%.

  • TherapeuticsMD's Gross Margin changed negligibly% to 100.00% in Q4 2023 from the same period last year, while for Dec 2023 it was 92.47%, marking a year-over-year decrease of 7491.00%. This contributed to the annual value of 100.00% for FY2023, which is 200.00% up from last year.
  • Per TherapeuticsMD's latest filing, its Gross Margin stood at 100.00% for Q4 2023, which was up 200.00% from -100.00% recorded in Q3 2023.
  • In the past 5 years, TherapeuticsMD's Gross Margin ranged from a high of 2,082.45% in Q1 2022 and a low of -100.00% during Q3 2023.
  • For the 3-year period, TherapeuticsMD's Gross Margin averaged around 269.47%, with its median value being 91.02% (2021).
  • Per our database at Business Quant, TherapeuticsMD's Gross Margin skyrocketed by 200,604bps in 2022 and then tumbled by 198,245bps in 2023.
  • Over the past 5 years, TherapeuticsMD's Gross Margin (Quarterly) stood at 118.39% in 2019, then tumbled by 4,311bps to 75.28% in 2020, then slumped by 64bps to 74.64% in 2021, then soared by 2,536bps to 100.00% in 2022, then remained steady at 100.00% in 2023.
  • Its Gross Margin stands at 100.00% for Q4 2023, versus -100.00% for Q3 2023 and 100.00% for Q2 2023.